18 results
Thumbnail

D2.165 - Geographic Disparities in Air Pollution and Th2-Mediated Airway Inflammation in Pediatric Asthma: A Cross-Sectional Study from Mexico City

Thumbnail

D2.167 - Impact of body mass index on oscillometry parameters in children with respiratory symptoms

Thumbnail

D2.168 - Impact of type two inflammation inflamation suppression on polyp burden in patients with nasal polyposis and concomitant asthma a comparative evaluation of biologic therapies

Thumbnail

D2.171 - Clinical and demographic characteristics associated with a classification as difficult-to-treat asthma: data from the EPI-ASTHMA study

Thumbnail

D2.172 - Effectiveness of Mepolizumab in patients with severe asthma and allergic rhinitis: Real-World Evidence from the TYREX Study

Thumbnail

D2.173 - Real-World Evidence From the TYREX Study on the effectiveness of Mepolizumab in patients with severe asthma and clinically relevant aeroallergen sensitization

Thumbnail

D2.174 - Association Between Environmental Conditions and Mold Sensitization in Children with Allergic Rhinitis and Asthma

Thumbnail

D2.175 - Five-Year Real-World Outcomes of Mepolizumab Treatment in Severe Eosinophilic Asthma

Thumbnail

D2.176 - Comparison of different treatment strategies for allergic rhinitis in children and their impact on bronchial asthma

Thumbnail

D2.179 - Chronic cough triggered by industrialised milk and wheat products

Thumbnail

D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)

Thumbnail

D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety

Thumbnail

D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A

Thumbnail

D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody

Thumbnail

D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria

Thumbnail

D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis

Thumbnail

D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)

Thumbnail

D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)